Elsevier

Clinical Lung Cancer

Volume 9, Issue 5, September 2008, Pages 262-270
Clinical Lung Cancer

Comprehensive Review
Extensive-Stage Small-Cell Lung Cancer: Evolution of Systemic Therapy and Future Directions

https://doi.org/10.3816/CLC.2008.n.041Get rights and content

Abstract

Extensive-stage small-cell lung cancer (ES-SCLC) is one of the most lethal malignancies, with a median overall survival of only 8-10 months with first-line chemotherapy despite response rates of 60%-80%. In the second-line setting, the prognosis is even more limited, with only 20%-30% of patients having a response and a median survival measured in weeks to months. This article will review systemic chemotherapy in first- and second-line treatment of patients with ES-SCLC and discuss novel therapeutic agents, cytotoxic and "targeted," with an emphasis on recently completed clinical trials and ongoing investigations.

References (146)

  • T Urban et al.

    Standard combination versus alternating chemotherapy in small cell lung cancer: a randomised clinical trial including 394 patients. ‘Petites Cellules’ Group

    Lung Cancer

    (1999)
  • D Mavroudis et al.

    A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer

    Ann Oncol

    (2001)
  • JP Sculier et al.

    A randomized study comparing etoposide and vindesine with or without cisplatin as induction therapy for small cell lung cancer. EORTC Lung Cancer Working Party

    Ann Oncol

    (1990)
  • M Altinbas et al.

    A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer

    J Thromb Haemost

    (2004)
  • JH Sohn et al.

    A phase II trial of fractionated irinotecan plus carboplatin for previously untreated extensive-disease small cell lung cancer

    Lung Cancer

    (2006)
  • W Akerley et al.

    Gemcitabine and irinotecan for patients with untreated extensive stage small cell lung cancer: SWOG 0119

    J Thorac Oncol

    (2007)
  • D Pectasides et al.

    Combination chemotherapy with cisplatin, etoposide and irinotecan in patients with extensive small-cell lung cancer: A phase II study of the Hellenic Co-operative Oncology Group

    Lung Cancer

    (2007)
  • J Vansteenkiste et al.

    Gemcitabine plus etoposide in chemonaive extensive disease small-cell lung cancer: a multi-centre phase II study

    Ann Oncol

    (2001)
  • PJ Hesketh et al.

    Phase II study of gemcitabine and cisplatin in patients with previously untreated extensive stage small cell lung cancer: Southwest Oncology Group Study 9718

    J Thorac Oncol

    (2007)
  • S Agelaki et al.

    A multicenter phase II study of the combination of gemcitabine and docetaxel in previously treated patients with small cell lung cancer

    Lung Cancer

    (2004)
  • I van der Lee et al.

    Single-agent gemcitabine in patients with resistant small-cell lung cancer

    Ann Oncol

    (2001)
  • JR Rigas et al.

    Randomized placebo-controlled trials of the matrix metalloproteinase inhibitor (MMPI), BAY12-9566 as adjuvant therapy for patients with small cell and non-small cell lung cancer

    J Clin Oncol

    (2003)
  • J Adams

    The proteasome: a suitable antineoplastic target

    Nat Rev Cancer

    (2004)
  • J Johl et al.

    The proteasome inhibitor PS-341 (bortezomib) in platinum (plat)-treated extensive-stage small cell lung cancer (E-SCLC): a SWOG (0327) phase II trial

    J Clin Oncl

    (2005)
  • JC Cusack et al.

    Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition

    Cancer Res

    (2001)
  • [Web site]. Bortezomib and topotecan in treating patients with advanced solid tumors

  • T Hirano et al.

    Quantitative distribution of cluster 1 small cell lung cancer antigen in cancerous and non-cancerous tissues, cultured cells and sera

    Jpn J Cancer Res

    (1989)
  • FV Fossella et al.

    Phase II Trial of BB-10901 (huN901-DM1) given weekly for four consecutive weeks every 6 weeks in patients with relapsed SCLC and CD56-positive small cell carcinoma

    J Clin Oncol

    (2005)
  • [Web site]. Weekly dosing with BB-10901 in patients with small cell lung cancer

  • SJ Antonia et al.

    Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer

    Clin Cancer Res

    (2006)
  • [Web site]. Vaccine therapy and chemotherapy with or without tretinoin in treating patients with extensive-stage small cell lung cancer

  • B Coiffier et al.

    CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

    N Engl J Med

    (2002)
  • H Kelly et al.

    Systemic therapy for metastatic colorectal cancer: current options, current evidence

    J Clin Oncol

    (2005)
  • HP Gerber et al.

    Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies

    Cancer Res

    (2005)
  • JL Pujol et al.

    Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01

    J Clin Oncol

    (2007)
  • AM Arnold et al.

    Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20

    J Clin Oncol

    (2007)
  • LE Heasley

    Autocrine and paracrine signaling through neuropeptide receptors in human cancer

    Oncogene

    (2001)
  • CM Rudin et al.

    Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103

    J Clin Oncol

    (2008)
  • Y Hasegawa et al.

    Vascular endothelial growth factor level as a prognostic determinant of small cell lung cancer in Japanese patients

    Intern Med

    (2005)
  • P Salven et al.

    High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer

    Int J Cancer

    (1998)
  • ES Kim et al.

    Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma

    Proc Natl Acad Sci U S A

    (2002)
  • GW Krystal et al.

    The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth

    Clin Cancer Res

    (2000)
  • GW Krystal et al.

    Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor

    Cancer Res

    (1996)
  • BE Johnson et al.

    Phase II study of imatinib in patients with small cell lung cancer

    Clin Cancer Res

    (2003)
  • L Boldrini et al.

    Expression and mutational status of c-kit in small-cell lung cancer: prognostic relevance

    Clin Cancer Res

    (2004)
  • C Wu et al.

    Overcoming cisplatin resistance by mTOR inhibitor in lung cancer

    Mol Cancer

    (2005)
  • [Web site]. Safety of RAD001 in combination with cisplatin and etoposide in lung cancer patients

  • NE Mills et al.

    Increased prevalence of K-ras oncogene mutations in lung adenocarcinoma

    Cancer Res

    (1995)
  • T Mitsudomi et al.

    Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines

    Oncogene

    (1991)
  • UK Khanzada et al.

    Potent inhibition of small-cell lung cancer cell growth by simvastatin reveals selective functions of Ras isoforms in growth factor signalling

    Oncogene

    (2006)
  • Cited by (0)

    Electronic forwarding or copying is a violation of US and International Copyright Laws.

    Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by CIG Media Group, LP, ISSN #1525-7304, provided the appropriate fee is paid directly to Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923 USA 978-750-8400.

    View full text